PMID- 15011958
OWN - NLM
STAT- MEDLINE
DCOM- 20040928
LR  - 20211203
IS  - 1566-5240 (Print)
IS  - 1566-5240 (Linking)
VI  - 4
IP  - 1
DP  - 2004 Feb
TI  - Non-antigen presenting effects of HLA-B27.
PG  - 41-9
AB  - Spondyloarthropathies (SpA) are a group of chronic rheumatic diseases, which show 
      a strong asoociation with human leukocyte antigen (HLA)-B27. Although the 
      association between HLA-B27 and the susceptibility to SpA was discovered thirty 
      years ago, the exact mechanism by which HLA-B27 predisposes to disease 
      development remains unclear. The classical role of MHC class I molecules is to 
      present peptides for CD8+ T cells. Therefore, it has been proposed that the 
      antigen presenting function of HLA-B27 is somehow altered in the patients 
      developing SpA. However, despite extensive research, the attempts to create a 
      comprehensive theory that would explain the role of HLA-B27 as an antigen 
      presenting molecule in the development of SpA have been unsuccessful. Reactive 
      arthritis (ReA) belongs to the group of SpA. It is a joint inflammation 
      developing after certain bacterial infections e.g. Salmonella, Yersinia, and 
      Chlamydia. Several unrelated observations indicate that HLA-B27 modulates the 
      interaction between ReA-triggering bacteria and host cell. These findings suggest 
      that HLA-B27 may possess functions, which are unrelated to antigen presentation. 
      In this paper, we summarize these findings and discuss their potential impact in 
      the development of SpA.
FAU - Penttinen, Markus A
AU  - Penttinen MA
AD  - National Public Health Institute, Department of Human Microbial Ecology and 
      Inflammation, Turku, Finland. markus.penttinen@utu.fi
FAU - Ekman, Paivi
AU  - Ekman P
FAU - Granfors, Kaisa
AU  - Granfors K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Curr Mol Med
JT  - Current molecular medicine
JID - 101093076
RN  - 0 (HLA-B27 Antigen)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (PHB2 protein, human)
RN  - 0 (Prohibitins)
RN  - 0 (beta 2-Microglobulin)
SB  - IM
MH  - Antigen Presentation/immunology
MH  - Disease Susceptibility/immunology/microbiology
MH  - Environmental Exposure/adverse effects
MH  - Gram-Negative Bacterial Infections/complications/*immunology/metabolism
MH  - HLA-B27 Antigen/*immunology
MH  - Histocompatibility Antigens Class I/immunology/metabolism
MH  - Humans
MH  - Lipopolysaccharides/pharmacology
MH  - Molecular Mimicry/immunology
MH  - Prohibitins
MH  - Rheumatic Diseases/etiology/*immunology/metabolism
MH  - Signal Transduction/drug effects
MH  - beta 2-Microglobulin/immunology/metabolism
RF  - 81
EDAT- 2004/03/12 05:00
MHDA- 2004/09/29 05:00
CRDT- 2004/03/12 05:00
PHST- 2004/03/12 05:00 [pubmed]
PHST- 2004/09/29 05:00 [medline]
PHST- 2004/03/12 05:00 [entrez]
AID - 10.2174/1566524043479275 [doi]
PST - ppublish
SO  - Curr Mol Med. 2004 Feb;4(1):41-9. doi: 10.2174/1566524043479275.